A5070290785- Synthesis and biological activity
- Peptidase Inhibition and Analysis
- HER2/EGFR in Cancer Research
- Radiopharmaceutical Chemistry and Applications
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Retinal Imaging and Analysis
- Retinal Diseases and Treatments
- Pancreatic and Hepatic Oncology Research
- Retinal and Optic Conditions
- Lung Cancer Research Studies
- Venous Thromboembolism Diagnosis and Management
- Cancer therapeutics and mechanisms
- Cerebral Venous Sinus Thrombosis
- Vasculitis and related conditions
- Neuroendocrine Tumor Research Advances
- Lung Cancer Treatments and Mutations
University Hospitals of Leicester NHS Trust
2024-2025
Leicester Royal Infirmary
2024
Larkin Community Hospital
2022
Father Muller Medical College Hospital
2022
St. Vincent's Medical Center
2022
University of Illinois Chicago
2022
University of Illinois Urbana-Champaign
2022
Institute of Medical Sciences
2022
Khyber Medical College
2022
New York University
2022
Purpose: Simlukafusp alfa [fibroblast activation protein α–targeted IL2 variant (FAP-IL2v)], a tumor-targeted immunocytokine, comprising an moiety with abolished CD25 binding fused to human IgG1, is directed against fibroblast α. This phase I, open-label, multicenter, dose-escalation, and extension study (NCT02627274) evaluated the safety, pharmacokinetics, pharmacodynamics, antitumor activity of FAP-IL2v in patients advanced/metastatic solid tumors. Patients Methods: Participants received...
Plain Language SummaryWhat was the purpose of FLAURA2 study?This is a summary main results clinical study in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC). The were published full 2023.NSCLC most common type cancer, but often not diagnosed until has spread beyond lungs described as 'metastastic' or 'advanced' disease.Epidermal growth factor (EGF) binds to EGFR (epidermal receptor) and leads signaling events that control how cells grow divide.Healthy transform into...
<p>Supplementary Figure S1. design. FAP-IL2v, fibroblast activation protein-α interleukin-2 variant; PD, progressive disease; QW, weekly.</p>
<div>Purpose:<p>Simlukafusp alfa [fibroblast activation protein α–targeted IL2 variant (FAP-IL2v)], a tumor-targeted immunocytokine, comprising an moiety with abolished CD25 binding fused to human IgG1, is directed against fibroblast α. This phase I, open-label, multicenter, dose-escalation, and extension study (NCT02627274) evaluated the safety, pharmacokinetics, pharmacodynamics, antitumor activity of FAP-IL2v in patients advanced/metastatic solid tumors.</p>Patients...
<p>Supplementary Figure S1. design. FAP-IL2v, fibroblast activation protein-α interleukin-2 variant; PD, progressive disease; QW, weekly.</p>
<p>Supplementary Methods</p>
<p>Supplementary Methods</p>
<div>Purpose:<p>Simlukafusp alfa [fibroblast activation protein α–targeted IL2 variant (FAP-IL2v)], a tumor-targeted immunocytokine, comprising an moiety with abolished CD25 binding fused to human IgG1, is directed against fibroblast α. This phase I, open-label, multicenter, dose-escalation, and extension study (NCT02627274) evaluated the safety, pharmacokinetics, pharmacodynamics, antitumor activity of FAP-IL2v in patients advanced/metastatic solid tumors.</p>Patients...
Objectives To evaluate the demographic and comorbid risk factors for cerebrovascular disease (CVD) hospitalization in patients with retinal artery occlusion (RAO) study impact on outcomes. Methods We conducted a retrospective cross-sectional using Nationwide Inpatient Sample (NIS, 2019). included 62,255 adults (age 18-65 years) primary diagnosis of CVD. The sample was divided by co-diagnosis RAO (N=1,700). A logistic regression model used to odds ratio (OR) association leading CVD RAO,...
To evaluate the risk factors and hospitalization outcomes for cerebrovascular diseases (CVD) in patients with vasculitis.